Anzeige
Mehr »
Login
Donnerstag, 20.03.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt einsteigen, bevor der Boom beginnt: Diese bahnbrechende Technologie erobert den Markt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J7EB | ISIN: FR0011341205 | Ticker-Symbol: 5NR
Tradegate
19.03.25
18:32 Uhr
3,582 Euro
-0,046
-1,27 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NANOBIOTIX SA Chart 1 Jahr
5-Tage-Chart
NANOBIOTIX SA 5-Tage-Chart
RealtimeGeldBriefZeit
3,4783,49609:35
3,4703,48409:35

Aktuelle News zur NANOBIOTIX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiCancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden3
DiNanobiotix tweaks J&J licensing deal for phase 3 cancer drug to eke out cash13
MoNanobiotix S.A.: NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-202685PARIS and CAMBRIDGE, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the "Company''), a late-stage clinical biotechnology company pioneering disruptive nanotherapeutic...
► Artikel lesen
13.03.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company2
13.03.Nanobiotix S.A. - 6-K, Report of foreign issuer1
NANOBIOTIX Aktie jetzt für 0€ handeln
12.02.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company1
12.02.Nanobiotix S.A. - 6-K, Report of foreign issuer-
29.01.Nanobiotix S.A. - 6-K, Report of foreign issuer-
21.01.Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study1
21.01.Nanobiotix S.A. - 6-K, Report of foreign issuer5
21.01.Nanobiotix S.A.: NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer172PARIS and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the "Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based...
► Artikel lesen
10.01.Nanobiotix S.A. - 6-K, Report of foreign issuer-
09.01.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company1
17.12.24Nanobiotix S.A.: NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 20242
17.12.24Nanobiotix S.A. - 6-K, Report of foreign issuer2
11.12.24Nanobiotix S.A.: Voting Rights and Shares Capital of the Company2
09.12.24Nanobiotix S.A.: NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer258Investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further evaluation in a randomized trial23 months median Overall Survival from date...
► Artikel lesen
09.12.24Nanobiotix S.A. - 6-K, Report of foreign issuer-
13.11.24Nanobiotix S.A.: Voting Rights and Shares Capital of the Company4
12.11.24Nanobiotix S.A.: NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms227Transferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for potential NBTXR3 regulatory submissionAdded expert industry leaders to Supervisory...
► Artikel lesen
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1